Novartis starts RELAXin as novel heart failure drug shows Phase III promise
This article was originally published in Scrip
Executive Summary
Novartis is off to talk to regulators about approving its novel investigational treatment for acute heart failure, serelaxin, on the basis of a single Phase III study after top-line data showed it met one of its two primary endpoints measuring dyspnoea, with the added bonus of reducing all-cause mortality at six months, a secondary endpoint.